XNASCVRX
Market cap412mUSD
Jan 15, Last price
17.00USD
1D
5.26%
1Q
109.88%
IPO
-34.79%
Name
CVRx Inc
Chart & Performance
P/E
—
P/S
10.50
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
39m
+74.89%
Net income
-41m
L-0.55%
CFO
-39m
L-8.57%
Earnings
Jan 23, 2025
Profile
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 39,295 74.89% | 22,469 72.36% | |||
Cost of revenue | 17,889 | 14,951 | |||
Unusual Expense (Income) | |||||
NOPBT | 21,406 | 7,518 | |||
NOPBT Margin | 54.48% | 33.46% | |||
Operating Taxes | 147 | 109 | |||
Tax Rate | 0.69% | 1.45% | |||
NOPAT | 21,259 | 7,409 | |||
Net income | (41,199) -0.55% | (41,428) -3.83% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,663 | 184 | |||
BB yield | -0.25% | -0.05% | |||
| Debt | |||||
Debt current | 231 | 222 | |||
Long-term debt | 32,933 | 6,981 | |||
Deferred revenue | |||||
Other long-term liabilities | (124) | 805 | |||
Net debt | (57,405) | (98,991) | |||
| Cash flow | |||||
Cash from operating activities | (39,021) | (42,677) | |||
CAPEX | (591) | (685) | |||
Cash from investing activities | (591) | (685) | |||
Cash from financing activities | 23,984 | 7,493 | |||
FCF | 14,984 | 1,101 | |||
| Balance | |||||
Cash | 90,569 | 106,194 | |||
Long term investments | |||||
Excess cash | 88,604 | 105,071 | |||
Stockholders' equity | (477,379) | (436,182) | |||
Invested Capital | 584,975 | 553,133 | |||
ROIC | 3.74% | 1.57% | |||
ROCE | 19.89% | 6.43% | |||
| EV | |||||
Common stock shares outstanding | 20,754 | 20,533 | |||
Price | 31.44 71.34% | 18.35 50.04% | |||
Market cap | 652,518 73.18% | 376,778 51.02% | |||
EV | 595,113 | 277,787 | |||
EBITDA | 21,928 | 7,930 | |||
EV/EBITDA | 27.14 | 35.03 | |||
Interest | 1,799 | 165 | |||
Interest/NOPBT | 8.40% | 2.19% | |||